Pacific Biosciences Of California (PACB) Non-Current Deffered Revenue (2011 - 2026)

Pacific Biosciences Of California's Non-Current Deffered Revenue history runs 16 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 39.3% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 39.3% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 33.41% from the prior year.
• Non-Current Deffered Revenue eased to $3.6 million in Q1 2026 per PACB's latest filing, from $3.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $25.2 million in Q1 2022 and bottomed at $1.8 million in Q3 2022.
• The 5-year median for Non-Current Deffered Revenue is $5.1 million (2023), against an average of $5.6 million.
• Biggest YoY gain for Non-Current Deffered Revenue was 343.92% in 2022; the steepest drop was 92.84% in 2022.
• Year by year, Non-Current Deffered Revenue stood at $1.8 million in 2022, then jumped by 208.25% to $5.5 million in 2023, then gained by 6.69% to $5.9 million in 2024, then tumbled by 33.41% to $3.9 million in 2025, then slipped by 9.54% to $3.6 million in 2026.
• Per Business Quant, the three latest PACB Non-Current Deffered Revenue figures stand at $3.6 million (Q1 2026), $3.9 million (Q4 2025), and $4.4 million (Q3 2025).